Abstract
Importance Schizophrenia is characterized with greater variability beyond the mean differences in brain structures. This variability is often assumed to be static, reflecting the presence of heterogeneous subgroups, but this assumption and alternative explanations remain untested.
Objective To test if gray matter volume (GMV) variability is more less in later stages of schizophrenia, and evaluate if a putative ‘spreading pattern’ with GMV deficits originating in one part of the brain and diffusing elsewhere explain the variability of schizophrenia.
Design, settings, and participants This study evaluated the regional GMV variability using MRI of 1,792 individuals with schizophrenia and 1,523 healthy controls (HCs), and the association of GMV variability with neurotransmitter and transcriptomic gene data in the human brain.
Main outcomes and measures Regional variability was evaluated by comparing the relative variability of patients to controls, using the relative mean-scaled log variability ratio (lnCVR). A network diffusion model (NDM) was employed to simulate the possible processes of GMV alteration across brain regions.
Results Compared with HCs, greater lnCVR (pFDR<0.05) was found in 50 regions in the whole patient group (n=1792; 762 females; mean[SD] age, 29.9[11.9] years), at a much greater frequency (p=5.0×10−13) in the first-episode drug-naïve subsample (73 regions) (n=478; mean[SD] illness duration, 0.548[0.459] years), compared to the chronic medicated subsample (28 regions) (n=398; mean[SD] illness duration, 14.0[10.4] years). The average lnCVR across all regions was greater in the first-episode than chronic subsample (t=10.8, p=1.7×10−7). The areas with largest lnCVR were located at frontotemporal cortex and thalamus (first-episode), or hippocampus and caudate (chronic); there was a significant correlation with case-control mean difference (r=0.367, p=6.7×10−4). We determined a gene expression map that correlated with the lnCVR map in schizophrenia (r=0.491, p=0.003). The NDM performed consistently (72.1% patients, pspin<0.001) in replicating GMV changes when simulated and observed values were compared.
Conclusion and relevance Brain-based heterogeneity is unlikely to be a static feature of schizophrenia; it is more pronounced at the onset of the disorder but reduced over the long term. Differences in the site of ‘origin’ of GMV changes in individual-level may explain the observed anatomical variability in schizophrenia.
Question No two individuals with schizophrenia have the same anatomical change in the brain. Is this variability a fixed feature of schizophrenia or does it become more pronounced at later stages? Is this variability explained by a putative ‘spreading pattern’ of gray matter deficits originating in one part of the brain and diffusing elsewhere?
Findings In 1,792 individuals with schizophrenia, neuroanatomical variability is not a fixed feature; it is more pronounced at the illness onset but less prominent in later stages. The neuroanatomical variability is associated with various molecular and neurobiological processes implicated in the neurodevelopmental etiology of schizophrenia. Differences in the site of ‘origin’ of gray matter deficits in each individual with schizophrenia explains most of the observed variability.
Meaning Our work finds support for a space-time interaction along a shared pathophysiological continuum (network-based trans-neuronal diffusion), as a possible explanatory model for inter-subject variability. These findings contribute to the understanding that inter-individual variability in schizophrenia may arise from a common cohesive process that varies in its state (across time) and space (across brain regions). This also raises the question of what dynamic processes contribute to the reducing heterogeneity over time in schizophrenia. Answering this question will be a key test to the neurobiological validity of the concept of schizophrenia.
Competing Interest Statement
LP reports personal fees for serving as chief editor from the Canadian Medical Association Journals, speaker/consultant fee from Janssen Canada and Otsuka Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Janssen Canada, Sunovion and Otsuka Canada outside the submitted work. All other authors disclose no conflict of interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted under the approval of the Medical Research Ethics Committee of Fudan University, Shanghai, China.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
